KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Current Assets (2016 - 2025)

Arbutus Biopharma's Current Assets history spans 15 years, with the latest figure at $97.4 million for Q3 2025.

  • For Q3 2025, Current Assets fell 26.61% year-over-year to $97.4 million; the TTM value through Sep 2025 reached $97.4 million, down 26.61%, while the annual FY2024 figure was $127.3 million, 3.57% down from the prior year.
  • Current Assets for Q3 2025 was $97.4 million at Arbutus Biopharma, down from $103.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $160.7 million in Q4 2021 and bottomed at $83.5 million in Q2 2021.
  • The 5-year median for Current Assets is $134.3 million (2024), against an average of $130.9 million.
  • The largest annual shift saw Current Assets surged 55.48% in 2021 before it crashed 30.43% in 2025.
  • A 5-year view of Current Assets shows it stood at $160.7 million in 2021, then decreased by 5.93% to $151.1 million in 2022, then dropped by 12.65% to $132.0 million in 2023, then dropped by 3.57% to $127.3 million in 2024, then decreased by 23.46% to $97.4 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Current Assets are $97.4 million (Q3 2025), $103.1 million (Q2 2025), and $116.8 million (Q1 2025).